Georgin-Lavialle, S
Moura, D S
Salvador, A
Chauvet-Gelinier, J-C
Launay, J-M
Damaj, G
Côté, F
Soucié, E
Chandesris, M-O
Barète, S
Grandpeix-Guyodo, C
Bachmeyer, C
Alyanakian, M-A
Aouba, A
Lortholary, O
Dubreuil, P
Teyssier, J-R
Trojak, B
Haffen, E
Vandel, P
Bonin, B
Beyne-Rauzy, Odile
de Gennes, Christian
Durieu, Isabelle
Fain, Olivier
Grosbois, Bernard
Guichard, Isabelle
Hamidou, Mohamed
Launay, David
Lavigne, Christian
Livideanu, Christina
Nicolini, Franck
Retornaz, Frederique
Arock, Michel
Arlet, Jean-Benoit
Hermine, O
Gaillard, R
,
Article History
Received: 28 April 2015
Revised: 24 October 2015
Accepted: 24 November 2015
First Online: 26 January 2016
Competing interests
: RG has received compensation as a member of the scientific advisory board of Janssen, Lundbeck, Roche, Takeda. He has served as consultant and/or speaker for Astra Zeneca, Pierre Fabre, Lilly, Otsuka, SANOFI, Servier and received compensation, and he has received research support from Servier. AS has consulted for Servier and received compensation. SGL has served as consultant and/or speaker for SOBI and Novartis and received financial help from SOBI and Bayer for travelling to congress. OH received research funding and honorarium from AB Science. The remaining authors declare no conflict of interest.